Literature DB >> 11764769

Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

L A Miller1, K Ratnam, D J Payne.   

Abstract

Combinations of beta-lactams and beta-lactamase inhibitors have become one of the most successful antibacterial strategies in our global battle against bacterial infections. The success of these agents is particularly emphasized by the continued efficacy of Augmenting (amoxicillin and clavulanate) after nearly 20 years of clinical use. The clinical situation now dictates that second-generation beta-lactamase inhibitors capable of encompassing both class A and class C beta-lactamases would combat emerging resistance and provide a vital addition to our armory of hospital antibiotics. This realization has generated a renewed interest in beta-lactamase inhibitors and improved the prospects for the delivery of such agents in the future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11764769     DOI: 10.1016/s1471-4892(01)00079-0

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  13 in total

1.  Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Authors:  Jennifer D Campbell; James S Lewis; M Leticia McElmeel; Letitia C Fulcher; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.

Authors:  Susanne Paukner; Lars Hesse; Andrej Prezelj; Tomaz Solmajer; Uros Urleb
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  Molecular dynamic simulations of the metallo-beta-lactamase from Bacteroides fragilis in the presence and absence of a tight-binding inhibitor.

Authors:  Freddie R Salsbury; Michael W Crowder; Stephen F Kingsmore; James J A Huntley
Journal:  J Mol Model       Date:  2008-11-28       Impact factor: 1.810

4.  Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.

Authors:  Vidhya Prakash; James S Lewis; Monica L Herrera; Brian L Wickes; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

Review 5.  Metallo-beta-lactamases: the quiet before the storm?

Authors:  Timothy R Walsh; Mark A Toleman; Laurent Poirel; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

6.  Property-Guided Synthesis of Aza-Tricyclic Indolines: Development of Gold Catalysis En Route.

Authors:  Patrick M Barbour; Wei Wang; Le Chang; Kasey L Pickard; Rana Rais; Barbara S Slusher; Xiang Wang
Journal:  Adv Synth Catal       Date:  2016-03-03       Impact factor: 5.837

7.  Crystal structure of a preacylation complex of the β-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-β-lactamase.

Authors:  Elizabeth A Rodkey; Sarah M Drawz; Jared M Sampson; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2012-09-26       Impact factor: 15.419

8.  In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

Authors:  William J Weiss; Peter J Petersen; Timothy M Murphy; Luanna Tardio; Youjun Yang; Patricia A Bradford; Aranapakam M Venkatesan; Takao Abe; Takeshi Isoda; Ado Mihira; Hideki Ushirogochi; Tsuyoshi Takasake; Steve Projan; John O'Connell; Tarek S Mansour
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.